Tablet

Voglibose 0.3mg

Voglibose

Alpha-glucosidase inhibitor that delays carbohydrate digestion to specifically control post-prandial hyperglycemia without significant systemic drug exposure. Uniquely approved in India for delaying onset of type 2 diabetes in patients with impaired glucose tolerance, adding a preventive dimension beyond standard glycemic management.

Strengths

0.2mg / 0.3mg

Packing

10 tablets/strip

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request Quotation WhatsApp

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition

Voglibose 0.2mg / 0.3mg

Dosage Form

Tablet

Available Strengths

0.2mg / 0.3mg

Packing

10 tablets/strip

Route of Administration

Oral, just before meals (3 times daily with each meal)

Dosage

0.2mg three times daily with meals initially; may increase to 0.3mg three times daily

Indications

Type 2 diabetes mellitus — post-prandial hyperglycemia control, impaired glucose tolerance (prevention of T2DM)

Country of Origin

India (WHO-GMP Certified)

Storage

Store at 25°C, protected from moisture

Shelf Life

36 months

Side Effects

Flatulence, abdominal distension, diarrhea, abdominal discomfort (most common and dose-related, often diminish with continued use)

Precautions

Treat hypoglycemia with glucose (not sucrose) as sucralose absorption is impaired; not for type 1 diabetes; avoid in severe GI disorders, cirrhosis, or renal impairment; must take with each meal

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Tablet

Glimepiride 2mg

Glimepiride

Third-generation sulfonylurea that stimulates pancreatic beta-cell insulin secretion via selective SUR1 receptor binding, offering a lower hypoglycemia risk compared to earlier sulfonylureas due to glucose-dependent activity. The most cost-effective oral antidiabetic agent in its class and a cornerstone of type 2 diabetes management in emerging markets.

1mg / 2mg / 3mg / 4mg

Tablet

Sitagliptin 100mg

Sitagliptin Phosphate

First-in-class DPP-4 inhibitor that amplifies incretin-mediated glucose-dependent insulin secretion while suppressing glucagon, offering glycemic control without weight gain or intrinsic hypoglycemia risk. Once-daily dosing, renal dose adjustment flexibility, and a decade-long cardiovascular safety record make it a globally preferred add-on antidiabetic.

25mg / 50mg / 100mg

Tablet

Vildagliptin 50mg

Vildagliptin

Selective DPP-4 inhibitor with potent enzyme inhibition that improves glycemic control through enhanced incretin-mediated insulin secretion and suppressed post-meal glucagon release. Widely prescribed as a fixed-dose combination with metformin (Galvusmet) offering convenient dual-mechanism therapy without weight gain.

50mg

Need bulk pricing for Voglibose 0.3mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote